<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01018823</url>
  </required_header>
  <id_info>
    <org_study_id>8835-037</org_study_id>
    <nct_id>NCT01018823</nct_id>
  </id_info>
  <brief_title>A Multiple Dose Study Of Ertugliflozin (PF-04971729, MK-8835) In Otherwise Healthy Overweight And Obese Volunteers (MK-8835-037)</brief_title>
  <official_title>A Phase 1, Randomized, Placebo-Controlled, Parallel Group, 14 Day Repeated Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-04971729 In Otherwise Healthy Overweight And Obese Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ertugliflozin (PF-04971729, MK-8835) is under development for the treatment of Type 2
      Diabetes. The primary purpose of this trial is to evaluate the safety and tolerability,
      pharmacokinetics and pharmacodynamics, of multiple oral doses of ertugliflozin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics, of
      multiple oral doses of ertugliflozin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 14, 2009</start_date>
  <completion_date type="Actual">March 18, 2010</completion_date>
  <primary_completion_date type="Actual">March 18, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experiencing an Adverse Event (AE)</measure>
    <time_frame>Up to 28 days postdose (Up to 42 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Discontinuing Study Drug Due to an AE</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) over the dosing interval tau (AUCtau) for ertugliflozin</measure>
    <time_frame>Up to 17 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of ertugliflozin</measure>
    <time_frame>Up to 17 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time taken to reach the maximum observed plasma concentration (Tmax) of ertugliflozin</measure>
    <time_frame>Up to 17 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ertugliflozin half life (t1/2)</measure>
    <time_frame>Up to 17 Days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent clearance (CL/F) after a single dose of ertugliflozin</measure>
    <time_frame>Up to 17 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution (Vz/F)</measure>
    <time_frame>Up to 17 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Accumulation Ratio of Area Under the Curve for the dosing interval of ertugliflozin (Rac[obs])</measure>
    <time_frame>Up to 17 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in 24-hour weighted mean glucose</measure>
    <time_frame>Baseline and Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in 24-hour urinary glucose excretion</measure>
    <time_frame>Baseline and Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in 24-hour plasma C-peptide</measure>
    <time_frame>Baseline and Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Inhibition of glucose reabsorption</measure>
    <time_frame>Baseline and Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in body weight</measure>
    <time_frame>Baseline and Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve over 8 hours (AUC[0-8]) for serum intact parathyroid hormone</measure>
    <time_frame>Up to 17 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve over 24 hours (AUC[0-24]) for serum intact parathyroid hormone</measure>
    <time_frame>Up to 17 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough concentration of serum intact parathyroid hormone (Ctrough)</measure>
    <time_frame>Up to 17 days</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Ertugliflozin 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin 1 mg, oral, once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertugliflozin up to 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin up to 5 mg, oral, once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertugliflozin up to 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin up to 25 mg, oral, once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertugliflozin up to 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin up to 100 mg, once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to Ertugliflozin once daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin</intervention_name>
    <description>Ertugliflozin oral dosing 1 mg, 5 mg, 25 mg, or 100 mg solutions/suspensions administered once daily for 14 days immediately after breakfast</description>
    <arm_group_label>Ertugliflozin 1 mg</arm_group_label>
    <arm_group_label>Ertugliflozin up to 5 mg</arm_group_label>
    <arm_group_label>Ertugliflozin up to 25 mg</arm_group_label>
    <arm_group_label>Ertugliflozin up to 100 mg</arm_group_label>
    <other_name>PF-04971729</other_name>
    <other_name>MK-8835</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Ertugliflozin</intervention_name>
    <description>Placebo oral dosing solutions/suspensions administered once daily for 14 days immediately after breakfast</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive.

        Body Mass Index (BMI) of 26.5 to 35.5 kg/m2; and a total body weight &gt;50 kg (110 lbs).

        Exclusion Criteria:

        Evidence or history of clinically significant hematological, renal, endocrine, pulmonary,
        gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease
        (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at
        time of dosing).

        Evidence of glycosuria, as defined by a positive urine dipstick test; Fasting (at least 10
        hours) serum triglyceride &gt;300 mg/dL; Fasting (at least 10 hours) LDL-cholesterol &gt;190
        mg/dL; Fasting (at least 10 hours) serum 25-OH Vitamin D concentration &lt;20 ng/mL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2009</study_first_submitted>
  <study_first_submitted_qc>November 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2009</study_first_posted>
  <last_update_submitted>October 30, 2017</last_update_submitted>
  <last_update_submitted_qc>October 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

